Guselkumab Continues Winning Streak in Crohn's Disease
Dual-acting IL-23 inhibitor tops placebo, ustekinumab in phase III trials
Source: medpagetoday.com
Stay updated with breaking news from Stool Frequency. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dual-acting IL-23 inhibitor tops placebo, ustekinumab in phase III trials
The golden rule of gastroenterology is to always heed the ‘call to stool’ when the urge strikes.
Gilead Sciences K.K.(Headquarter: Chiyoda-ku, Tokyo, General Manager: Kennet Brysting, “Gilead”), Eisai Co., Ltd.
Validity and reliability of the Amharic version of EORTC-QLQ-CR29 among colorectal cancer patients in Ethiopia
Risankizumab takes effect within the first few weeks and has enduring effects in Crohn's disease, phase 3 trials suggest.